289
Participants
Start Date
March 30, 2022
Primary Completion Date
January 24, 2024
Study Completion Date
January 24, 2024
Ferric Citrate 1 GM Oral Tablet [AURYXIA]
All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Placebo
All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Nephrology Associates of Western NY, Amherst
Spartanburg Nephrology Associates, Spartanburg
Nephrology and Hypertension Specialists, PC, Dalton
Dialysis Clinic, Inc., Albany
Associates in Nephrology, Fort Myers
Dialysis Clinic, Inc., Knoxville
Major Health Partners, Shelbyville
Kidney Associates of Kansas City, Kansas City
Arkansas Nephrology & Hypertension Clinic, Pine Bluff
South Texas Renal Care Group, San Antonio
South Texas Renal Care Group, San Antonio
Clinical Advancement Center, PLLC, San Antonio
South Texas Renal Care Group, San Antonio
South Texas Renal Care Group, Live Oak
South Texas Renal Care Group, San Antonio
Rocky Mountain Kidney Care, Lone Tree
High Desert Nephrology Associates, Gallup
Balboa Research SMO, Chula Vista
Balboa Research SMO, La Mesa
Balboa Research SMO, Escondido
Balboa Research SMO - Kearney Mesa, San Diego
Balboa Research SMO, El Centro
Nephrology-Hypertension Associates of Central NJ, South River
Collaborators (1)
Akebia Therapeutics
INDUSTRY
USRC Kidney Research
NETWORK